← Back to Search

Procedure

Early Surgical Hematoma Evacuation for Stroke (ENRICH Trial)

N/A
Waitlist Available
Led By Jonathan Ratcliff, MD, MPH
Research Sponsored by Nico Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30, 90, 120, and 180 days
Awards & highlights

ENRICH Trial Summary

This trial is testing whether early surgery to remove a brain bleed is better than standard medical care.

Eligible Conditions
  • Stroke

ENRICH Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30, 90, 120, and 180 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30, 90, 120, and 180 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Functional Improvement - mRS
Secondary outcome measures
Economic
Safety - Hemorrhage Volume
Safety - Procedure-Related Mortality

ENRICH Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Early Surgical Hematoma EvacuationExperimental Treatment1 Intervention
Subjects will receive early surgical hematoma evacuation using Minimally Invasive Parafascicular Surgery (MIPS).
Group II: Medical ManagementActive Control1 Intervention
Subjects will receive standard of care medical management for ICH.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Early Surgical Hematoma Evacuation
2016
N/A
~300

Find a Location

Who is running the clinical trial?

Nico CorporationLead Sponsor
3 Previous Clinical Trials
5,140 Total Patients Enrolled
Emory UniversityOTHER
1,638 Previous Clinical Trials
2,560,242 Total Patients Enrolled
30 Trials studying Stroke
348,032 Patients Enrolled for Stroke
Jonathan Ratcliff, MD, MPHPrincipal Investigator1-877-572-5511 | ENRICH@emory.edu | Emory University School of Medicine

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this experiment require participants to be at least 18 years old?

"To be considered for this trial, participants must have an age between 18 and 80. There are 56 studies available to those under the legal age of consent while 294 trials can be accessed by individuals over 65 years old."

Answered by AI

How widespread is the implementation of this clinical trial?

"A total of 30 healthcare facilities are participating in the trial, including Vanderbilt University Medical Center (Nashville), NorthShore University Health System (Evanston), and USC Keck School of Medicine (Los Angeles). The other 27 locations can be found online."

Answered by AI

Are there any opportunities for individuals to participate in this experiment?

"Unfortunately, the clinical trial detailed on clinicialtrials.gov is not presently enrolling patients; this study was initially posted to the website in December 2016 and its last update came through in August 2022. Although no longer recruiting candidates, there are 368 other trials actively looking for participants as of now."

Answered by AI

For whom is this study best suited?

"This trial aims to recruit 300 participants aged 18-80 who have experienced cerebral hemorrhage. In order to be eligible, patients must meet the following criteria: between 30 and 80 mL of intracranial bleeding volume, a pre-randomization head CT demonstrating an acute spontaneous primary ICH, GCS score ranging from 5 - 14, Modified Rankin Score 0 or 1 with study intervention initiated within 24 hours after stroke symptoms occur (or when patient was last known to be well if onset is unclear)."

Answered by AI
Recent research and studies
~36 spots leftby Apr 2025